One retrospective observational study that explored the efficacy of ICIs or ICIs in combination with chemotherapy in EGFR mutant NSCLC included a patient population of whom 13% had uncommon EGFR mutations, in particular ex20ins, G719X, one L861Q. Here, EGFR is linked to non-small cell lung carcinoma.